Our team
Who are the Endeavor consortium partners?
Click on each team leader to find out more.
Prof. Dr. Sheila Krishnadath
Prof. Dr. Magnus Nilsson
Prof. Dr. Silvio Danese
Prof. Jacintha O’Sullivan
Prof. Dr. Hans Neubauer
Prof. Dr. Nikolas Stoecklein
Prof. Dr. Guillaume Piessen
Prof. Dr. Veerle Coupé
Prof. Dr. Ines Gockel
Kristi Kruusmaa
Sanne Hoefnagel, MD
Our team
Endeavor Team Members
Click on each member to find out more.
Prof. Dr. Riccardo Rosati
Prof. Dr. Stefan Van Dongen
Prof. Dr. Guido Van Hal
Prof. Dr. Heiko De Schepper
Dr. Edi Viale
Prof. Dr. Albrecht Hoffmeister
Prof. Dr. Pernilla Lagergren
Prof. Dr. Michael Patrick Achiam
Dr. Rui Neves
Dr. Francesco Vito Mandarino
Dr. René Thieme
Dr. Federica Ungaro
Dr. Edoardo Vespa
Prof. Dr. Francisco Baldaque Silva
Prof. Dr. Ann Driessen
Dr. Daniel Doerr
Dr. Fredrik Klevebro
Dr. Henrik Maltzman
Dr. Thomas Botelberge
Dr. Patrick Sven Plum
Dr. Dominiek De Wulf
Dr. Marjolein Greuter
Dr. David Tate
Dr. Michiel De Maat
Prof. Dr. Pieter De Wint
Dr. Elisabeth Macken
Dr. Souad Bouhadan
Masami Omae, MD
Nastaran Riahi
Monica Sudarsanam, MD
Martin Wyckmans, MD
Our team
Central contacts
Ms Luka Van der Veken
Mr Toon Mertens
What? Why? Where?
About ENDEAVOR
Endeavor WHAT?
Endeavor WHY?
Endeavor WHO?
Endeavor WHAT?
WHAT is the ENDEAVOR research project?
ENDEAVOR is a European research project, funded by the European Union*, and is short for “Endoscopic brush cytology and single cell clonal dynamics of early esophageal adenocarcinoma for defining cost effective surveillance strategies and prediction of cancer recurrence”.
In other words, with the ENDEAVOR project we would like to develop a cost-effective method to identify patients with Barrett’s esophagus (BE) who are at high risk of developing esophageal adenocarcinoma (EAC), a subtype of esophageal cancer, in order to select the best treatment and surveillance program for each individual. Thereby we aim to improve the patient’s quality of life, assist clinicians to make better-informed decisions using a patient-centered approach and reduce healthcare costs.
Get a visual overview and find out more about our Research
Endeavor WHAT?
WHY do we perform the ENDEAVOR research project?
Patients with BE have a higher risk of developing EAC. Currently, it is impossible to predict which of the BE patients with early cancer will respond completely to endoscopic therapy and will remain stable in remission and which patients will have recurrent disease. As a consequence, all treated BE patients need to remain in frequent endoscopic surveillance. This leads to overtreatment of >90% of BE patients and potential undertreatment of the small group with aggressive disease. The lack of effective risk stratification results in frequent follow up endoscopies after the primary treatment and a low-cost effectiveness of endoscopic therapies, poor quality of life of patients and poor satisfaction of care providers.
Therefore, biological tools are required to precisely identify those BE patients at high-risk of progression to EAC, which can be applied for risk stratification and directing treatment. The current practice without risk stratification results in healthcare costs being needlessly high and places an extra burden on the patient and their care givers. Implementing a cost-effective risk stratification method for early EAC in BE patients is therefore a major unmet medical need.
Get a visual overview and find out more about our Research
Endeavor WHAT?
WHO is leading the ENDEAVOR research project?
Do you have a question? Please let us know
Phone:
+99 (0) 101 0000 888
Email:
endeavor@uza.be